DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 46
Price : Single User: US $ 3500  US $ 2800 Corporate User: US $ 10500  US $ 7875
This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1)

- The report reviews DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Overview 6
Therapeutics Development 7
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Products under Development by Stage of Development 7
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Products under Development by Therapy Area 8
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Products under Development by Indication 9
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Products under Development by Companies 12
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Companies Involved in Therapeutics Development 20
Celgene Corporation 20
Eli Lilly and Company 21
Merck KGaA 22
Onxeo SA 23
Vertex Pharmaceuticals Incorporated 24
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Drug Profiles 25
AsiDNA - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CC-115 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
LY-3023414 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
M-3814 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
VX-984 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Dormant Projects 33
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Discontinued Products 34
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Featured News & Press Releases 35
Jul 04, 2016: Onxeo receives USPTO Notice of Allowance for key AsiDNA patent, extending IP protection in the U.S. until 2031 35
Jul 04, 2016: Onxeo receives USPTO Notice of Allowance for key AsiDNATM patent, extending IP protection in the U.S. until 2031 36
Jun 27, 2016: Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA 37
Jun 17, 2015: Eli Lilly and Company Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy 38
May 30, 2015: DNA Therapeutics presents encouraging results for first-in-class pan DNA repair inhibitor 38
Mar 05, 2014: Curie-Cancer and DNA Therapeutics partner in the fight against cancers that resist conventional therapies 39
Mar 26, 2012: DNA Therapeutics Announces Completion Of Two First Dose Escalations In DRIIM Trial 41
Jan 10, 2012: DNA Therapeutics Announces USPTO's Decision To Grant Third Dbait Patent 42
Jan 03, 2012: DNA Therapeutics Announces Completion Of Two Week Course Of Patients In First Cohort Of DRIIM Trial 42
Jan 03, 2012: DNA Therapeutics Announces Completion Of Two Week Course Of Treatment Of Patients In First Dose Cohort Of DRIIM Trial 43
Nov 25, 2011: DNA Therapeutics's Dbait Receives Chinese Patent Allowance For Treatment Of Metastatic Melanoma 43
Aug 22, 2011: DNA Therapeutics Receives Clinical Trial Authorization From French Competent Authority For DNA Therapeutics' First-In-Human Trial 44
Mar 31, 2011: DNA Therapeutics Completes Regulatory Toxicology Studies Of DT01 In Rat And Monkey 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Celgene Corporation, H2 2016 20
Pipeline by Eli Lilly and Company, H2 2016 21
Pipeline by Merck KGaA, H2 2016 22
Pipeline by Onxeo SA, H2 2016 23
Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 24
Dormant Projects, H2 2016 33
Discontinued Products, H2 2016 34

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Actions, H2 2016 15
Number of Products by Routes of Administration, H2 2016 16
Number of Products by Stage and Routes of Administration, H2 2016 16
Number of Products by Molecule Types, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 18
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global Lysozyme Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 18-May-2017        Price: US 3480 Onwards        Pages: 123
    Lysozyme is an enzyme that plays an important role in the prevention of bacterial infections. Lysozyme is an enzyme used to break down bacterial cell walls to improve protein or nucleic acid extraction efficiency. Lysozymes (muramidases) are a family of enzymes with antimicrobial activity characterized by the ability to damage the cell wall of bacteria. The enzyme acts by catalyzing the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidogly......
  • North America Lysozyme Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 18-May-2017        Price: US 4480 Onwards        Pages: 122
    Lysozyme is an enzyme that plays an important role in the prevention of bacterial infections. Lysozyme is an enzyme used to break down bacterial cell walls to improve protein or nucleic acid extraction efficiency. Lysozymes (muramidases) are a family of enzymes with antimicrobial activity characterized by the ability to damage the cell wall of bacteria. The enzyme acts by catalyzing the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidogly......
  • Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017
    Published: 12-May-2017        Price: US 1750 Onwards        Pages: 115
    DelveInsight's, "Janus Kinase Inhibitor (JAK) Inhibitors-Competitive Landscape, Technology and Pipeline Analysis, 2017", report provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on the Janus Kinase (JAK) Inhibitorsdealing with all the pipeline drugs, comparative anal......
  • North America Collagenase Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 05-May-2017        Price: US 4480 Onwards        Pages: 123
    Collagenase, obtained from Clostridium histolyticum, is an enzyme used for tissue dissociation in vitro and thus for isolation of many different types of cells. These isolated cells are then used for numerous clinical and research applications.Scope of the Report:This report focuses on the Collagenase in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and application.......
  • North America Restriction Endonucleases Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 01-May-2017        Price: US 4480 Onwards        Pages: 120
    Restriction Endonuclease is an enzyme that cuts DNA at or near specific recognition nucleotide sequences known as restriction sites. They are the enzymes that are found in the bacteria and are harvested from them for their use in research and commercial aspects. Restriction enzymes are commonly classified into four types, which differ in their structure and whether they cut their DNA substrate at their recognition site, or if the recognition and cleavage sites are separate from one another.......
  • Global Pullulanase Sales Market Report 2017
    Published: 26-Apr-2017        Price: US 4000 Onwards        Pages: 107
    In this report, the global Pullulanase market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Pullulanase for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeas......
  • Asia-Pacific Laccase Market Report 2017
    Published: 26-Apr-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the Asia-Pacific Laccase market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Laccase for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Korea - Taiwan - India......
  • Asia-Pacific Xylanase Market Report 2017
    Published: 26-Apr-2017        Price: US 4000 Onwards        Pages: 123
    In this report, the Asia-Pacific Xylanase market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Xylanase for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Korea - Taiwan - Ind......
  • Global Endoenzyme Market Research Report 2017
    Published: 18-Apr-2017        Price: US 2900 Onwards        Pages: 100
    In this report, the global Endoenzyme market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Endoenzyme in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs